FRα Radioconjugate Pipeline Ovarian Cancer — PatSnap Eureka
FRα Radioconjugate Pipeline: Post-Mirvetuximab Resistance in Ovarian Cancer
Folate receptor alpha (FRα/FOLR1) remains expressed in MIRV-refractory disease. Patent analysis reveals a converging pipeline of radioligand therapies, next-generation ADCs, and theranostic strategies targeting this retained vulnerability.
Why FRα Remains a Viable Target After Mirvetuximab Failure
Folate receptor alpha (FRα, encoded by FOLR1) is a GPI-anchored cell-surface glycoprotein overexpressed on epithelial ovarian cancer cells — including high-grade serous, endometrioid, and clear-cell histologies — while exhibiting limited expression in normal tissues. This differential expression profile underpins the therapeutic window exploited by all FRα-directed approaches identified in the patent dataset.
A critical finding across retrieved filings is that FRα-expressing tumors retain receptor presentation even in contexts resistant to maytansinoid-based payloads — i.e., MIRV-based mechanisms. This retained target expression rationalizes payload-switching strategies, including the shift toward radionuclide conjugation. Novartis filings specifically describe FRα-expressing tumors as candidates for radioligand therapy regardless of prior systemic treatment history, implying an expectation of maintained target expression post-MIRV failure.
Retrieved patent filings from life sciences innovators across Immunomedics, Novartis, Sutro Biopharma, and Daiichi Sankyo all converge on FRα/FOLR1 as the singular molecular target — underscoring the concentrated focus on this receptor within the post-MIRV resistance landscape. According to NCI data, ovarian cancer remains one of the most lethal gynaecologic malignancies, reinforcing the unmet need driving this pipeline.
The companion diagnostic dimension is equally critical: FRα expression quantification, as claimed in the Immunomedics 2022 patent (US11382979B2), provides the biomarker framework for patient selection that extends directly into the resistance context — confirming maintained target expression before pivoting to radioconjugate or alternative ADC therapy.
Three Converging Strategies in the Post-MIRV FRα Pipeline
Patent filings from 2022–2024 reveal three distinct modality clusters — radioligand therapy, next-generation ADCs with alternative payloads, and companion diagnostics — each addressing the MIRV resistance challenge from a different mechanistic angle.
FRα-Targeted Radioconjugates — Novartis AG
Novartis has filed two distinct patents representing the most direct radioconjugate-specific pipeline signal in the dataset. The 2022 filing (US20220143212A1) provides foundational composition-of-matter claims for an FRα-targeting radioligand with both therapeutic and diagnostic (imaging) applications — a theranostic design architecture. The 2024 filing (US20240108764A1) extends this with dosing regimen claims and patient selection methodology for anti-FRα antibody–radionuclide conjugates.
Theranostic design · Dosing regimen claims filed 2024STRO-002 & Post-MIRV ADC Strategies — Sutro Biopharma
Sutro Biopharma's 2024 filing (US20240342293A1) is the most direct post-MIRV resistance claim in the dataset, explicitly describing STRO-002 — an anti-FRα ADC with site-specific conjugation — for patients resistant to mirvetuximab soravtansine-gynx (MIRV). A companion filing (US20240050591A1) describes engineered anti-FOLR1 antibodies with improved drug-to-antibody ratio (DAR) homogeneity, impacting both efficacy and tolerability.
Explicit MIRV-resistance claim · Site-specific conjugationTOP1i FRα ADC — Daiichi Sankyo Co., Ltd.
Daiichi Sankyo's 2023 filing (US20230173107A1) discloses FRα ADCs armed with a topoisomerase I inhibitor (TOP1i) payload — a distinct cytotoxic mechanism via DNA damage that bypasses maytansinoid resistance mechanisms. This follows Daiichi Sankyo's established expertise in TOP1i ADC platforms. The mechanistic orthogonality to MIRV's DM4 payload makes this a rational post-MIRV strategy.
TOP1i payload · Mechanistically distinct from MIRVCombination Regimens & Broad IP — Immunomedics (Gilead)
Immunomedics holds the broadest FRα IP portfolio in the dataset with four filings. The 2023 filing (US20230321278A1) claims combination of anti-FRα ADC with anti-VEGF agents for patients previously treated with platinum, PARP inhibitors, or other FRα-targeted therapies. Two additional filings (US20220054646A1; US20240115728A1) explicitly enumerate radionuclides among claimed payloads, preserving broad IP coverage over radionuclide-conjugated FRα antibody scaffolds.
Anti-VEGF combination · Radionuclide IP preservedFRα Pipeline Filing Trends & Assignee Distribution
Visualising the patent filing velocity and assignee concentration across the FRα-targeted pipeline, as retrieved from PatSnap Eureka searches spanning 2022–2024.
FRα-Targeted Patent Filings by Year (2022–2024)
Filing activity accelerated from 3 patents in 2022 to 4 in 2024, with the 2024 cohort including the most advanced post-MIRV resistance claims.
Patent Filings by Assignee — FRα Pipeline (2022–2024)
Immunomedics (Gilead) leads with 4 filings; Novartis and Sutro Biopharma each hold 2; Daiichi Sankyo holds 1 in the retrieved dataset.
Novartis FRα Radioconjugate: From Composition to Dosing Regimen
The Novartis radioligand pipeline represents the clearest translational progression in the dataset — moving from composition-of-matter claims in 2022 to dosing regimen and patient selection claims in 2024.
Theranostic Architecture (2022)
The 2022 Novartis filing (US20220143212A1) provides foundational composition-of-matter claims for an FRα-targeting radioligand encompassing both therapeutic and diagnostic imaging applications. This dual utility signals a theranostic design architecture where the radioligand serves as both a SPECT/PET imaging agent and a therapeutic — enabling patient selection and dosimetry before treatment.
Dosing Regimen Claims (2024)
The 2024 Novartis filing (US20240108764A1) extends the framework with dosing regimen claims and patient selection methodology, describing methods of determining dose and administration schedule for anti-FRα antibody–radionuclide conjugates. The progression from composition claims to dosing and regimen claims is consistent with translational advancement from initial construct design toward IND-enabling or early clinical stages.
Key FRα Pipeline Patents — Assignee, Modality & Development Signal
| Patent ID | Assignee | Filed | Modality | Key Claim Signal |
|---|---|---|---|---|
| US20240108764A1 | Novartis AG | 2024 | Radioligand | Dosing regimen & patient selection for anti-FRα antibody–radionuclide conjugates |
| US20220143212A1 | Novartis AG | 2022 | Radioligand | Composition of matter — FRα radioligand for therapeutic and imaging use (theranostic) |
| US20240342293A1 | Sutro Biopharma | 2024 | Next-Gen ADC | STRO-002 for patients explicitly resistant to mirvetuximab soravtansine-gynx (MIRV) |
| US20240050591A1 | Sutro Biopharma | 2024 | Next-Gen ADC | Engineered anti-FOLR1 antibodies with site-specific conjugation for improved DAR homogeneity |
| US20230173107A1 | Daiichi Sankyo | 2023 | Next-Gen ADC | Anti-FRα ADC with TOP1i payload — mechanistically distinct from MIRV's maytansinoid |
Monitor FRα Filing Activity in Real Time
PatSnap Eureka tracks new FRα patent filings across all jurisdictions as they publish.
How the Pipeline Addresses MIRV Resistance Mechanisms
The accelerated approval of mirvetuximab soravtansine-gynx (MIRV) as the first FRα-targeted ADC has established FRα as a clinically actionable vulnerability in ovarian cancer, but the inevitable emergence of resistance has catalyzed a secondary wave of FRα-directed modalities. The patent dataset reveals three mechanistic rationales for maintaining therapeutic engagement at the FRα axis after MIRV failure.
Payload mechanism switching is the most direct resistance strategy. MIRV's DM4 payload targets tubulin polymerization. Daiichi Sankyo's TOP1i-armed FRα ADC (US20230173107A1) uses DNA damage via topoisomerase I inhibition — a completely orthogonal cytotoxic mechanism that bypasses DM4-specific resistance pathways. This approach mirrors the success of EMA-approved TOP1i ADC strategies in other HER2-expressing tumor types.
Target-retained radionuclide delivery exploits the observation that FRα expression is maintained in MIRV-resistant disease. Novartis filings describe FRα-expressing tumors as candidates for radioligand therapy regardless of prior treatment history. The radionuclide payload's cytotoxic mechanism (ionizing radiation) is entirely independent of the resistance mechanisms that develop against maytansinoids, providing a clean therapeutic rationale. Patent landscape analytics from PatSnap confirm this is an emerging category distinct from prior ADC IP.
Site-specific conjugation optimization via Sutro Biopharma's STRO-002 platform addresses resistance driven by ADC heterogeneity. Engineered site-specific conjugation sites improve DAR homogeneity, potentially reducing off-target toxicity and improving the therapeutic index in patients who may have experienced tolerability issues with MIRV. The 2024 filing (US20240342293A1) is the only retrieved patent that explicitly claims treatment of MIRV-resistant patients, making it the most direct post-resistance IP signal in the dataset. According to WHO cancer reports, ovarian cancer recurrence rates underscore the clinical urgency of post-resistance strategies.
FRα Radioconjugate Pipeline in Ovarian Cancer — key questions answered
FRα (folate receptor alpha, encoded by FOLR1) is a GPI-anchored cell-surface glycoprotein overexpressed on epithelial ovarian cancer cells, including high-grade serous, endometrioid, and clear-cell histologies, while exhibiting limited expression in normal tissues. This differential expression profile underpins the therapeutic window exploited by all FRα-directed approaches.
Mirvetuximab soravtansine-gynx (MIRV) is the first FRα-targeted antibody-drug conjugate (ADC) to receive accelerated approval, establishing FRα as a clinically actionable vulnerability. However, the inevitable emergence of resistance has catalyzed a secondary wave of FRα-directed modalities — most prominently radioconjugates (radioligand therapy, RLT) alongside next-generation ADCs — seeking to maintain therapeutic engagement at the FRα axis in refractory disease.
Novartis has filed two distinct patents: a 2022 filing (US20220143212A1) providing foundational composition-of-matter claims for an FRα-targeting radioligand with both therapeutic and diagnostic applications, and a 2024 filing (US20240108764A1) extending this with dosing regimen claims and patient selection methodology. The progression from composition claims to dosing and regimen claims is consistent with translational advancement from initial construct design toward IND-enabling or early clinical stages.
Sutro Biopharma's 2024 patent filing (US20240342293A1) describes STRO-002, an anti-FRα ADC with site-specific conjugation, and explicitly claims methods of treating patients resistant to mirvetuximab soravtansine-gynx (MIRV). This is the most direct post-MIRV resistance claim retrieved in the patent dataset. A companion filing (US20240050591A1) also describes engineered anti-FOLR1 antibodies with site-specific conjugation architecture designed for improved homogeneity of ADC drug-to-antibody ratio (DAR).
Daiichi Sankyo's 2023 patent filing (US20230173107A1) discloses FRα ADCs armed with a topoisomerase I inhibitor (TOP1i) payload, a distinct cytotoxic mechanism (DNA damage via TOP1 inhibition) that bypasses maytansinoid resistance mechanisms. This follows Daiichi Sankyo's established expertise in TOP1i ADC platforms.
The dataset signals that FRα-expressing tumors retain receptor presentation even in contexts resistant to maytansinoid-based payloads (i.e., MIRV-based mechanisms), which rationalizes the rationale for payload-switching strategies — including the shift toward radionuclide conjugation. Novartis filings specifically describe FRα-expressing tumors as candidates for radioligand therapy regardless of prior systemic treatment history, implying an expectation of retained target expression post-MIRV failure.
Still have questions? Let PatSnap Eureka search the FRα patent database for you.
Ask Eureka About FRα RadioconjugatesMap Every FRα Patent Before Your Competitors Do
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D.
References
- Novartis AG — "Radioligand Therapy of FRα Expressing Tumors" (US20240108764A1, 2024)
- Novartis AG — "Compositions and Methods for Treating Ovarian Cancer Using a Folate Receptor Alpha-Targeting Radioligand" (US20220143212A1, 2022)
- Sutro Biopharma — "Anti-FRα Antibody-Drug Conjugate and Combination Regimen in the Treatment of Cancer" (US20240342293A1, 2024)
- Sutro Biopharma — "Anti-Folate Receptor Alpha Antibodies and Uses Thereof" (US20240050591A1, 2024)
- Daiichi Sankyo Co., Ltd. — "Anti-Folate Receptor Alpha Antibody-Drug Conjugates and Their Uses" (US20230173107A1, 2023)
- Immunomedics, Inc. — "Combination Therapy with Anti-Folate Receptor Alpha ADC and Anti-VEGF Agent in Treating Cancer" (US20230321278A1, 2023)
- Immunomedics, Inc. — "Anti-Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof" (US20230390408A1, 2023)
- Immunomedics, Inc. — "Anti-Folate Receptor Alpha Antibodies and Immunoconjugates and Uses Thereof" (US20220054646A1, 2022)
- Immunomedics, Inc. — "Anti-Folate Receptor Alpha Antibodies and Immunoconjugates and Uses Thereof" (US20240115728A1, 2024)
- Immunomedics, Inc. — "Folate Receptor Alpha as a Diagnostic and Prognostic Marker for Folate Receptor Alpha-Expressing Cancers" (US11382979B2, 2022)
- National Cancer Institute (NCI) — Cancer Statistics and Ovarian Cancer Information
- World Health Organization (WHO) — Global Cancer Observatory: Ovarian Cancer
- European Medicines Agency (EMA) — ADC Regulatory Approvals and Guidance
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. Patent abstracts retrieved via PatSnap Eureka. This report represents a snapshot of innovation signals within the retrieved dataset only and should not be interpreted as a comprehensive view of the full clinical pipeline, regulatory landscape, or scientific consensus in this therapeutic area.
PatSnap Eureka searches patents and research to answer instantly.